Study wrapper · #603
The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.
Editor's note
In rats subjected to myocardial ischemia-reperfusion injury, researchers reported that hexarelin, a synthetic growth hormone-releasing peptide given for seven days, improved cardiac systolic function, reduced oxidative stress (malondialdehyde), and increased surviving cardiomyocytes. Mechanistically they describe downregulated IL-1beta and upregulated IL-1Ra, effects blocked by a GHS-receptor antagonist, implicating GHSR1a-mediated modulation of IL-1 signaling. Benefits were reported as slightly greater than equimolar ghrelin. This fits hexarelin's consistent rodent cardiac literature but remains a single-species acute model with a specific dosing regimen. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide, in rats whose hearts were injured by briefly cutting off then restoring blood flow. Rats received hexarelin, ghrelin (a natural hormone), or salt water for seven days. Hexarelin improved the heart's pumping, lowered a marker of oxidative stress, and left more heart-muscle cells alive. The team linked these effects to changes in an inflammation signal (less IL-1beta, more of its natural blocker IL-1Ra); a drug that blocks hexarelin's receptor removed the benefit, pointing to a specific receptor pathway. Hexarelin's effects were slightly stronger than ghrelin's. The abstract reports no adverse events. These are preclinical findings in rats; human research would be needed before drawing any clinical conclusions.